Roger Cady

Chief Medical Officer, Slate Medicines

Appears in 1 story

Last updated Aug 18, 2026

Stories

Slate Medicines merges with Fulcrum Therapeutics to reach Nasdaq

Money Moves

As of August 2026: Leading clinical strategy for SLTE-1009

Fulcrum Therapeutics spent two years watching its two lead drugs fail. On August 17, 2026, the shell that remained agreed to merge with Slate Medicines, a privately held migraine startup, in an all-stock deal backed by a $245 million private placement.

Updated Aug 18